

PRODUCT INFORMATION

EGFR Peptide (human, mouse) (myristoylated) (trifluoroacetate salt)

Item No. 36897

Formal Name: tetradecanoyl-L-arginyl-L-lysyl-L-arginyl-L-threonyl-L-leucyl-L-arginyl-L-arginyl-L-leucine, trifluoroacetate salt

Synonyms: Epidermal Growth Factor Receptor Peptide, Myr-Arg-Lys-Arg-Thr-Leu-Arg-Arg-Leu-OH, N-myristoyl-RKRTLRL

Peptide Sequence: Myr-RKRTLRL-OH

MF: C₆₀H₁₁₇N₂₁O₁₁ • XCF₃COOH


FW: 1,308.7

Purity: ≥95%

Supplied as: A solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

EGFR Peptide (human, mouse) (myristoylated) (trifluoroacetate salt) is supplied as a solid. A stock solution may be made by dissolving the EGFR Peptide (human, mouse) (myristoylated) (trifluoroacetate salt) in the solvent of choice, which should be purged with an inert gas. EGFR Peptide (human, mouse) (myristoylated) (trifluoroacetate salt) is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of EGFR Peptide (human, mouse) (myristoylated) (trifluoroacetate salt) in these solvents is approximately 10 mg/ml.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of EGFR Peptide (human, mouse) (myristoylated) (trifluoroacetate salt) can be prepared by directly dissolving the solid in aqueous buffers. The solubility of EGFR Peptide (human, mouse) (myristoylated) (trifluoroacetate salt) in PBS (pH 7.2) is approximately 2 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

EGFR peptide (myristoylated) is a synthetic peptide inhibitor of PKC (IC₅₀ = 5 μM) that corresponds to an amino acid sequence from the intracellular region of EGFR.¹ It reverses resistance to doxorubicin (Item No. 15007) in doxorubicin-resistant UV-2237M (UV-2237M-ADR^R) fibrosarcoma cells when used at a concentration of 1 μM.

References

- O'Brian, C.A., Ward, N.E., Liskamp, R.M., *et al.* A novel N-myristylated synthetic octapeptide inhibits protein kinase C activity and partially reverses murine fibrosarcoma cell resistance to adriamycin. *Invest. New Drugs* **9**(2), 169-179 (1991).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 08/18/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM